Advanced nonsquamous NSCLC: First-line ICI-chemo tops bevacizumab-chemo in OSApril 25, 2022Lung Cancer
Unresectable stage III NSCLC: Platinum-doublet chemotherapy beneficial as second-line therapyApril 25, 2022Lung Cancer
Stage I NSCLC: No real-world survival benefit with tegafur-uracil chemotherapyApril 25, 2022Lung Cancer
Advanced refractory ROS1+ NSCLC: Lorlatinib is safe and effective in real-world settingApril 25, 2022Lung Cancer
Pyrotinib boosts survival in lapatinib-resistant HER2+ breast cancer in the real worldApril 25, 2022Breast Cancer
Preoperative imaging of T1 tumors estimates postoperative pathology size in early invasive breast cancerApril 25, 2022Breast Cancer
Excellent prognosis in young patients with node-negative TNBC and high sTILApril 25, 2022Breast Cancer
Breast cancer: Depression and hormone therapy significant risk factors for worse fatigue trajectoryApril 25, 2022Breast Cancer
Switching to lapatinib shows promise in HER2+ trastuzumab-refractory metastatic breast cancerApril 25, 2022Breast Cancer
Abemaciclib+ET shows a manageable safety profile in HR+/HER2-, high-risk early breast cancerApril 25, 2022Breast Cancer
